Sentinel Lymph Node Sampling for Early Gastric Cancer —Preliminary Results of A North American Prospective Study
ConclusionsThis study represents the first prospective feasibility evaluation of sentinel lymph node sampling for early gastric cancer in North America with promising preliminary results. The dual tracer method was superior to single agent blue dye in identifying sentinel nodal basins. Considerable further study is necessary to verify the safety and utility of SLN mapping in North American patients with early gastric adenocarcinoma.
There are several different types of gastric neoplasm, depending on the cell of origin. The most common gastric neoplasm is adenocarcinoma followed by lymphoma, gastrointestinal stromal tumours (GISTs), carcinoids and other rarer neoplasms. Gastric adenocarcinoma is one of the most common cancers worldwide, especially in the Far East. In the UK, the incidence is lower, but the poor prognosis of late stage disease means the impact on population health is significant. Most patients present with advanced disease at diagnosis.
is a lethal condition where 5-year survival remains at about 15%. There are two main subtypes of oesophageal cancer, squamous cell carcinoma (OSCC) and adenocarcinoma (OAC). OSCC usually affects the middle third of the oesophagus and is associated with smoking, alcohol and low socio-economic status. OAC affects the lower third of the oesophagus and is associated with gastro-oesophageal reflux disease. The UK has the highest incidence of OAC in the world and it is rising. Treatment may be palliative or curative.
CONCLUSIONS: The tumor regression grading system is useful in evaluating tumor response to neoadjuvant therapy, but more work is needed to refine and unify the system. PMID: 32825946 [PubMed - as supplied by publisher]
Abstract Based on clinical outcomes in colorectal cancer, high microsatellite instability (MSI-H) has recently been approved by the Food and Drug Administration (FDA) as a genetic test to select patients for immunotherapy targeting PD-1 and/or CTLA-4 without limitation to cancer type. However, it is unclear whether the MSI-H would broadly alter the tumor microenvironment to confer the therapeutic response of different cancer types to immunotherapy. To fill in this gap, we performed an in silico analysis of tumor immunity among different MSI statuses in five cancer types. We found that consistent with clinical resp...
ConclusionPatients with proximally located adenocarcinoma, or with lymph node metastases are at a higher risk for BRMs and patients fare better after treatment of isolated BRM.
Emerging evidence supports combining immune checkpoint inhibitors (ICIs) with conventional or targeted therapies to enhance ICI antitumour activity and broaden the spectrum of patients who respond to ICIs. Here, we present the safety and preliminary efficacy of ramucirumab, an anti-VEGFR2 IgG1, plus durvalumab, an anti –PD-L1 IgG1, in previously treated patients with advanced non–small-cell lung cancer (NSCLC), gastric/gastro-oesophageal junction adenocarcinoma (gastric/GEJ), or hepatocellular carcinoma (HCC).
It remains uncertain whether Siewert III tumors should be treated as esophageal or gastric cancers. Neoadjuvant therapy has been shown to improve survival in both esophageal and gastric trials. Randomized control trials comparing neoadjuvant chemotherapy versus chemoradiation should help define the most optimal treatment regimen. Surgical treatment follows general oncology principals: resect to negative margins with complete lymph node dissection, and, the extent of resection often extends more proximal onto the esophagus in addition to the total/subtotal gastrectomy.
Conditions: Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma Intervention: Drug: Anlotinib Hydrochloride With Nivolumab Sponsor: Shanghai Zhongshan Hospital Not yet recruiting
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Conclusion: The magnifying endoscopy diagnostic algorithm for gastric cancer may not be useful for esophageal or EGJ adenocarcinomas because of the low visibility of DLs, especially in Siewert type I adenocarcinoma.